The published science behind iPSC exosome therapy. Peer-reviewed research across multiple therapeutic indications.
⚠️ The following represents a curated selection of peer-reviewed published research. All citations are from indexed journals. Exosome therapy is a rapidly evolving field; clinical applications should always be guided by a qualified physician.
Exosomes derived from stem cells significantly upregulated COL1A1 and COL3A1 gene expression in aged fibroblasts, demonstrating direct collagen stimulation at the transcriptional level.
iPSC-derived exosomes reversed multiple hallmarks of skin aging including reduced MMP-1 (collagen-degrading enzyme) activity and increased ECM deposition in ex vivo skin models.
Clinical trial demonstrated 40% reduction in melanin index at 8 weeks following exosome intradermal therapy, superior to conventional depigmentation treatments.
Exosome treatment significantly increased hair follicle count and hair shaft diameter through Wnt/β-catenin pathway activation in androgenetic alopecia models.
In a head-to-head pilot study, exosome-treated patients showed greater hair density increase at 6 months compared to PRP-treated controls, with fewer sessions required.
Systemically administered exosomes successfully penetrated the blood-brain barrier and reduced neuroinflammatory markers in Parkinson's disease animal models.
Administration of iPSC exosomes in the sub-acute stroke window significantly improved neurological function scores and reduced infarct volume in preclinical models.